TAXUS Liberte Long Offers Stent Length of 38 mm
Boston Scientific's TAXUS Liberte Long Paclitaxel-Eluting Coronary Stent System is designed for long lesions. At 38 mm, it is the longest available DES, providing doctors an option that can potentially reduce the number of stents used in more complex cases.
The TAXUS ATLAS Long Lesion Trial reported a significant 79 percent reduction in the rate of nine-month myocardial infarction for the TAXUS Liberte Long Stent as compared to the TAXUS Express Stent control (1.3 percent vs. 6.3 percent). At two years, the composite measure of cardiac death or myocardial infarction showed a significant 63 percent reduction for the TAXUS Liberte Long Stent compared to the TAXUS Express Stent (3.5 percent vs. 9.4 percent). The rate of stent thrombosis at two years was zero percent for the TAXUS Liberte Long Stent and 0.8 percent for the TAXUS Express Stent.
The stent received FDA approval in July 2009.
For more information: www.bostonscientific.com